ULTZERA @page { } table { border-collapse:collapse; border-spacing:0; empty-cells:show } td, th { vertical-align:top; font-size:12pt;} h1, h2, h3, h4, h5, h6 { clear:both } ol, ul { margin:0; padding:0;} li { list-style: none; margin:0; padding:0;} <!-- "li span.odfLiEnd" - IE 7 issue--> li span. { clear: both; line-height:0; width:0; height:0; margin:0; padding:0; } span.footnodeNumber { padding-right:1em; } span.annotation_style_by_filter { font-size:95%; font-family:Arial; background-color:#fff000; margin:0; border:0; padding:0; } * { margin:0;} .gr1 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr10 { font-size:24pt; writing-mode:lr-tb; } .gr11 { font-size:24pt; writing-mode:lr-tb; min-height:4.181cm;min-width:0cm;padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr2 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.125cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.125cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; min-height:1.27cm;} .gr3 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr4 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr5 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr6 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr7 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr8 { font-size:24pt; writing-mode:lr-tb; padding-top:0.13cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; } .gr9 { color:#ffffff; font-size:18pt; font-style:normal; font-weight:normal; line-height:100%; margin-bottom:0cm; margin-left:0cm; margin-right:0cm; margin-top:0cm; padding-bottom:0.13cm; padding-left:0.25cm; padding-right:0.25cm; padding-top:0.13cm; text-align:left ! important; text-indent:0cm; text-shadow:none; text-decoration:none ! important; writing-mode:lr-tb; } .P1 { font-size:14pt; } .P10 { margin-left:0cm; margin-right:0cm; text-align:right ! important; text-indent:0cm; } .P11 { margin-left:0cm; margin-right:0cm; text-align:right ! important; text-indent:0cm; writing-mode:lr-tb; } .P12 { margin-left:0cm; margin-right:0cm; text-indent:0cm; } .P13 { text-align:center ! important; writing-mode:lr-tb; } .P14 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-indent:0cm; } .P15 { margin-left:0cm; margin-right:0cm; margin-top:0.617cm; margin-bottom:0cm; text-indent:0cm; } .P16 { margin-left:0cm; margin-right:0cm; margin-top:0.529cm; margin-bottom:0cm; text-indent:0cm; } .P17 { margin-left:0cm; margin-right:0cm; margin-top:0.44cm; margin-bottom:0cm; text-indent:0cm; } .P18 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; text-indent:0cm; } .P19 { margin-left:0cm; margin-right:0cm; margin-top:0.246cm; margin-bottom:0cm; text-indent:0cm; } .P2 { text-align:right ! important; font-size:14pt; } .P20 { margin-left:3.175cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; text-indent:-0.635cm; } .P21 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P22 { margin-left:0cm; margin-right:0cm; margin-top:0.211cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P23 { margin-left:2.063cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; line-height:80%; text-indent:-0.793cm; } .P24 { margin-left:0cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P25 { margin-left:0cm; margin-right:0cm; margin-top:0.123cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P26 { margin-left:0cm; margin-right:0cm; margin-top:0.282cm; margin-bottom:0cm; text-indent:0cm; } .P27 { margin-left:0cm; margin-right:0cm; margin-top:0.529cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P28 { margin-left:0cm; margin-right:0cm; margin-top:0.396cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P29 { margin-left:0cm; margin-right:0cm; margin-top:0.44cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P3 { writing-mode:lr-tb; } .P30 { margin-left:0cm; margin-right:0cm; margin-top:0.617cm; margin-bottom:0cm; line-height:80%; text-indent:0cm; } .P31 { margin-left:0cm; margin-right:0cm; margin-top:0.176cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P32 { margin-left:0cm; margin-right:0cm; margin-top:0.158cm; margin-bottom:0cm; line-height:90%; text-indent:0cm; } .P4 { margin-left:0cm; margin-right:0cm; line-height:100%; text-indent:0cm; writing-mode:lr-tb; } .P5 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:center ! important; text-indent:0cm; writing-mode:lr-tb; } .P6 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; } .P7 { margin-left:0cm; margin-right:0cm; line-height:100%; text-align:right ! important; text-indent:0cm; writing-mode:lr-tb; } .P8 { margin-left:0cm; margin-right:0cm; text-indent:0cm; writing-mode:lr-tb; } .P9 { margin-left:0cm; margin-right:0cm; text-align:center ! important; text-indent:0cm; writing-mode:lr-tb; } .T10 { text-shadow:1pt 1pt; } .T11 { font-size:24pt; text-shadow:1pt 1pt; } .T12 { font-size:36pt; text-shadow:1pt 1pt; } .T13 { font-size:28pt; text-shadow:1pt 1pt; } .T14 { font-size:32pt; text-shadow:1pt 1pt; } .T15 { text-shadow:1pt 1pt; } .T16 { text-shadow:1pt 1pt; font-weight:bold; } .T17 { text-shadow:1pt 1pt; } .T18 { font-size:24pt; text-shadow:1pt 1pt; } .T19 { font-size:24pt; text-shadow:1pt 1pt; } .T2 { font-size:12pt; text-shadow:1pt 1pt; } .T20 { font-size:20pt; text-shadow:1pt 1pt; } .T21 { font-size:18pt; text-shadow:1pt 1pt; text-decoration:underline; font-weight:bold; } .T22 { font-size:20pt; text-shadow:1pt 1pt; text-decoration:underline; font-weight:bold; } .T23 { font-size:18pt; text-shadow:1pt 1pt; } .T24 { font-size:18pt; font-style:italic; text-shadow:1pt 1pt; } .T25 { font-size:14pt; text-shadow:1pt 1pt; } .T26 { text-shadow:1pt 1pt; text-decoration:underline; font-weight:bold; } .T27 { color:#ffffcc; font-size:51pt; text-shadow:1pt 1pt; font-weight:bold; } .T28 { font-size:36pt; text-shadow:1pt 1pt; font-weight:bold; } .T29 { font-size:20pt; font-style:italic; text-shadow:1pt 1pt; } .T3 { font-size:10pt; text-shadow:1pt 1pt; } .T30 { font-size:36pt; text-shadow:1pt 1pt; } .T31 { font-size:40pt; text-shadow:1pt 1pt; } .T32 { font-size:28pt; text-shadow:1pt 1pt; } .T33 { font-size:18pt; text-shadow:1pt 1pt; } .T34 { font-size:20pt; text-shadow:1pt 1pt; } .T4 { color:#eaeaea; font-size:12pt; text-shadow:1pt 1pt; } .T5 { color:#b2b2b2; font-size:48pt; text-shadow:1pt 1pt; } .T6 { font-style:italic; text-shadow:1pt 1pt; } .T7 { color:#ffffff; font-size:24pt; text-shadow:1pt 1pt; } .T8 { color:#ffffff; font-size:24pt; text-shadow:1pt 1pt; } .T9 { font-size:36pt; text-shadow:1pt 1pt; font-weight:bold; } <!-- ODF styles with no properties representable as CSS --> .dp1 .dp2 .dp3 .dp4 .T1 { } ULTZERA Helicobacter pylori1982 Populazioaren %50 infektaturik %15 lotutako gaixotasuna Ultzera peptikoa  urdailekoa %80, duodenokoa %100 Farmako eraginkorrakProtoi-ponparen inhibitzaileak (PPI) Bismutozko konposatuak Antibiotikoak Tratamendurako irizpideak Desagertzearen indizeak >%90  Eragin desiragaitzak <%5  Pazienteak betetzeko errazak  Antibiotikoekiko erresistentzi-tasa txikiak  Laburra (7-10 egun)  Merkea Tratamenduaren arrakasta baldintzatuko duten faktoreakIraupena 7 egun (USA 10-14) Erresistentzi antimikrobianoak Metronidazol %40 Betetze maila + %60 betetzea  desagerpena %96 - %60 betetzea  desagerpena %69 Eredu hirukoitza klasikoaBismutozko konposatua + Metronidazol + Tetraziklina  + Merkea, desagerpena %90  - Metronidazolekiko erresistentziak, eragin desiragaitzak, pilula asko, iraupen luzea (14 egun) Beste eredu hirukoitzakPPI + klaritromizina + amoxizilina/metronidazol + Laburrago (7 egun), eragin desiragaitz gutxiago, desagerpena >%85 - Klaritromizinarekiko erresistentziak, bigarren mailako erresistentziak  PPI + lebofloxazino + amoxizilina Ranitidina + Bismuto zitratoa + 1-2 Antibiotiko + Bismutoaren eragin antimikrobianoa, desagerpena %85 - Urdailaren jariopen azidoaren inhibizioa Eredu laukoitzaPPI + Bismutozko gatzak + Tetraziklina + Metronidazol + desagerpena > %90  - pilula asko, iraupen luzea (10-14 egun) AIEEPazienteen %15-25  ultzera (%2-4 odol-jarioa) Eragin gastrointestinalekin lotutako hilkortasuna %0.22 Arrisku faktoreak Adina Ultzeraren aurreko historia AIEE ezberdinak eta/edo kortikoideak elkarketa Dosi altuak Tratamenduaren iraupena Beste gaixotasun larriak Antikoagulatzaileen erabilpena H. pylori Prebentzioa Arrisku altuko pazienteengan Toxikotasun gutxiagoko farmakoak erabili Mukosaren babesleak erabili PPI Misoprostol AIEETratamendua AIEE kendu edo ordezkatu H. Pylori desagertarazi PPI, H2 antagonistak BIRFLUXU GASTROESOFAGIKOA BIRFLUXU GASTROESOFAGIKOA Urdailaren edukiak hestegorrira pasatzea sintomak edo hestegorriaren asaldura inflamatorioak eragiten Populazioaren %40 (%5 egunero, %35-45 hilabetean behin, %40-60 esofagitisa) Faktore ezberdinen arteko desoreka: –Baimentzaileak (hiato-hernia, hestegorriko beheko esfinterraren disfuntzioa) –Erasotzaileak (Azido eta pepsinaren jarioketa, behazuna, arearen entzimak) –Babesleak (mukua, hestegorriaren aklaramendua) Pirosia, korrokadak, regurgitazioa, gainlistuketa... BIRFLUXU GASTROESOFAGIKOA Tratamenduaren helburuak Sintomak hobetzea Esofagitisa sendatzea Berragerpenak ekiditzea Konplikazioak tratatzea (estenosia, ultzera, odol-jarioa...) Jariopenaren inhibitzaileen beharra iragartzen duten faktoreak Sintomen iraupena (>10 urte) Sintomen maiztasuna (>3 aldiz egunean) Aurreko tratamendua jariopenaren inhibitzaileekin Birfluxu erradiologikoa Hiato-hernia Erretzea EEI-ren presioa <10 mmHg Berragerpenak iragartzen duten faktoreak Sintomen agerpena egunean Esofagitis maila Erretzea Stressa Birfluxu erradiologikoa Hiato-hernia Sendaketa geldoa tratamenduarekin Obesitatea EEI-ren presioa <7 mmHg Tratamendu farmakologikoa H2 antagonistak (ranitidina, famotidina…) –Sintomen hobekuntza %85 –Esofagitisa I-II (%75-90 sendatu), esofagitisa III-IV (%40-50 sendatu)  jariopen azidoaren inhibizioa +  tratamenduaren iraupena  mukosaren asalduren sendaketa Ponparen inhibitzaileak (omeprazola, lansoprazola, pantoprazola) Prokinetikoak (zisaprida, zinitaprida, metoklopramida, betanekol)  EEI-ren presioa,  hestegorriaren mugimenduak,  urdaileko hustuketa –Esofagitisa I-II (%63 sendatu), Mukosaren babesleak (sukralfatoa, misoprostol) –H2 antagonisten antzeko eraginkortasuna Antiazidoak
